CHAPTER 2.1 48 Supplementary table 4. Number and percentage of patients who received <50% or >= 50% target doses of heart failure medication by the 4 comparison groups Registry population RCT population N= 16922 All N=46914 (100%) RCT- eligible N= 26104 (56%) RCT-noneligible N=20810 (44%) ACEI/ARB >0 - <50% 5417(37%) 13196(33%) 7693(30%) 5503(38%) >=50% 9242(63%) 27230(67%) 18171(70%) 9059(62%) Beta-blocker >0 - <50% 7096(50%) 15954(39%) 9474(36%) 6480(42%) >=50% 6968(50%) 25502(61%) 16610(64%) 8892(58%) Aldosterone antagonist >0 - <50% 40(1%) 80(0%) 46(0%) 34(1%) >=50% 5051(99%) 17112(100%) 10226(100%) 6846(99%) Values are expressed as number (%) Denominator for target doses include only those with dose information available, and for individual drugs which have designated target doses according to the ESC guidelines Percentages may not add up to 100% due to rounding. ACE, angiotensin- converting enzyme inhibitor; ARB, angiotensin-II receptor blocker
RkJQdWJsaXNoZXIy MjY0ODMw